Hematopoietic stem cells in chronic myeloid leukemia

Archives of Medical Research

Volumn 34, Issue 6, 2003, Pages 496-506

  Petzer, Andreas L ^a   Gunsilius, Eberhard ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Leukemia; Myeloproliferative disorder; Philadelphia chromosome

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB;

CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG TOLERABILITY; ENDOTHELIUM CELL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; LOW DRUG DOSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; REVIEW; STEM CELL TRANSPLANTATION; VASCULAR ENDOTHELIUM;

EID: 0346374772     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2003.09.005     Document Type: Review

References (133)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. 1960;132:1497.
2. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. (letter) Nature. 243:1973;290-293.
3. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 36:1984;93-99.
4. Raskind W.H., Fialkow P.J. The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res. 49:1987;127-167.
5. Melo J.V., Gordon D.E., Cross N.C., Goldman J.M. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood. 81:1993;158-165.
6. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 247:1990;1079-1082.
7. McWhirter J.R., Wang J.Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol. 11:1991;1553-1565.
8. Muller A.J., Young J.C., Pendergast A.M., Pondel M., Landau N.R., Littman D.R., Witte O.N. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol Cell Biol. 11:1991;1785-1792.
9. Buckle A.M., Mottram R., Pierce A., Lucas G.S., Russell N., Miyan J.A., Whetton A.D. The effect of Bcr-Abl protein tyrosine kinase on maturation and proliferation of primitive haematopoietic cells. Mol Med. 6:2000;892-902.
10. Bedi A., Zehnbauer B.A., Barber J.P., Sharkis S.J., Jones R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:1994;2038-2044.
11. McGahon A., Bissonnette R., Schmitt M., Cotter K.M., Green D.R., Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 83:1994;1179-1187.
12. Pasternak G., Hochhaus A., Schultheis B., Hehlmann R. Chronic myelogenous leukemia: molecular and cellular aspects. J Cancer Res Clin Oncol. 124:1998;643-660.
13. Bhatia R., Verfaillie C.M. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Blood. 91:1998;3414-3422.
14. Kantarjian H.M., Deisseroth A., Kurzrock R., Estrov Z., Talpaz M. Chronic myelogenous leukemia: a concise update. Blood. 82:1993;691-703.
15. Goldman J.M. Chronic myeloid leukemia. Curr Opin Hematol. 4:1997;277-285.
16. Fialkow P.J., Jacobson R.J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 63:1977;125-130.
17. Eaves C., Cashman J., Eaves A. Defective regulation of leukemic hematopoiesis in chronic myeloid leukemia. Leuk Res. 22:1998;1085-1096.
18. Eaves A.C., Eaves C.J. Growth control in leukemia. Prog Clin Biol Res. 354A:1990;223-236.
19. Eaves C., Miller C., Cashman J., Conneally E., Petzer A., Zandstra P., Eaves A. Hematopoietic stem cells: inferences from in vivo assays. Stem Cells. 15:(Suppl 1):1997;1-5.
20. Coulombel L., Eaves A.C., Eaves C.J. Enzymatic treatment of long-term human marrow cultures reveals the preferential location of primitive hemopoietic progenitors in the adherent layer. Blood. 62:1983;291-297.
21. Coulombel L., Kalousek D.K., Eaves C.J., Gupta C.M., Eaves A.C. Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. N Engl J Med. 308:1983;1493-1498.
22. Goto T., Nishikori M., Arlin Z., Gee T., Kempin S., Burchenal J., Strife A., Wisniewski D., Lambek C., Little C., Jhanwar S., Chaganti R., Clarkson B. Growth characteristics of leukemic and normal hematopoietic cells in Ph'+ chronic myelogenous leukemia and effects of intensive treatment. Blood. 59:1982;793-808.
23. Talpaz M., Kantarjian H.M., McCredie K., Trujillo J.M., Keating M.J., Gutterman J.U. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 314:1986;1065-1069.
24. Petzer A.L., Hochenburger E., Haun M., Grunewald K., Hoflehner E., Sill H., Linkesch W., Gastl G., Gunsilius E. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration. J Hematother Stem Cell Res. 11:2002;293-300.
25. Petzer A.L., Eaves C.J., Lansdorp P.M., Ponchio L., Barnett M.J., Eaves A.C. Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood. 88:1996;2162-2171.
26. Eaves C., Udomsakdi C., Cashman J., Barnett M., Eaves A. The biology of normal and neoplastic stem cells in CML. Leuk Lymphoma. 11:(Suppl 1):1993;245-253.
27. Udomsakdi C., Eaves C.J., Lansdorp P.M., Eaves A.C. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood. 80:1992;2522-2530.
28. Verfaillie C.M., Miller W.J., Boylan K., McGlave P.B. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood. 79:1992;1003-1010.
29. Udomsakdi C., Eaves C.J., Lansdorp P.M., Eaves A.C. Phenotypic heterogeneity of primitive leukemic hematopoietic cells in patients with chronic myeloid leukemia. Blood. 80:1992;2522-2530.
30. Verfaillie C.M., Bhatia R., Miller W., Mortari F., Roy V., Burger S., McCullough J., Stieglbauer K., Dewald G., Heimfeld S., Miller J.S., McGlave P.B. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood. 87:1996;4770-4779.
31. Udomsakdi C., Eaves C.J., Swolin B., Reid D.S., Barnett M.J., Eaves A.C. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci USA. 89:1992;6192-6196.
32. Barnett M.J., Eaves C.J., Phillips G.L., Gascoyne R.D., Hogge D.E., Horsman D.E., Humphries R.K., Klingemann H.G., Lansdorp P.M., Nantel S.H. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood. 84:1994;724-732.
33. Barnett M.J., Eaves C.J., Phillips G.L., Hogge D.E., Klingemann H.G., Lansdorp P.M., Nantel S.H., Reece D.E., Shepherd J.D., Sutherland H.J. Autografting in chronic myeloid leukemia with cultured marrow: update of the Vancouver Study. Stem Cells. 1:(Suppl 3):1993;64-66.
34. Petzer A.L., Hogge D.E., Landsdorp P.M., Reid D.S., Eaves C.J. Self-renewal of primitive human hematopoietic cells (long-term-culture- initiating cells) in vitro and their expansion in defined medium. Proc Natl Acad Sci USA. 93:1996;1470-1474.
35. Petzer A.L., Eaves C.J., Barnett M.J., Eaves A.C. Selective expansion of primitive normal hematopoietic cells in cytokine-supplemented cultures of purified cells from patients with chronic myeloid leukemia. Blood. 90:1997;64-69.
36. Ponchio L., Conneally E., Eaves C. Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood. 86:1995;3314-3321.
37. Eaves A.C., Cashman J.D., Gaboury L.A., Kalousek D.K., Eaves C.J. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA. 83:1986;5306-5310.
38. Traycoff C.M., Halstead B., Rice S., McMahel J., Srour E.F., Cornetta K. Chronic myelogenous leukaemia CD34+ cells exit G0/G1 phases of cell cycle more rapidly than normal marrow CD34+ cells. Br J Haematol. 102:1998;759-767.
39. Peters D.G., Klucher K.M., Perlingeiro R.C., Dessain S.K., Koh E.Y., Daley G.Q. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. Oncogene. 20:2001;2636-2646.
40. Li S., Gillessen S., Tomasson M.H., Gilliland D.G., Van Etten R.A. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL. Blood. 97:2001;1442-1450.
41. Chang J.M., Metcalf D., Lang R.A., Gonda T.J., Johnson G.R. Nonneoplastic hematopoietic myeloproliferative syndrome induced by dysregulated multi-CSF (IL-3) expression. Blood. 73:1989;1487-1497.
42. Wong P.M., Chung S.W., Dunbar C.E., Bodine D.M., Ruscetti S., Nienhuis A.W. Retrovirus-mediated transfer and expression of the interleukin-3 gene in mouse hematopoietic cells result in a myeloproliferative disorder. Mol Cell Biol. 9:1989;798-808.
43. Just U., Katsuno M., Stocking C., Spooncer E., Dexter M. Targeted in vivo infection with a retroviral vector carrying the interleukin-3 (multi-CSF) gene leads to immortalization and leukemic transformation of primitive hematopoietic progenitor cells. Growth Factors. 9:1993;41-55.
44. Jiang X., Fujisaki T., Nicolini F., Berger M., Holyoake T., Eisterer W., Eaves C., Eaves A. Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia. Leukemia. 14:2000;1112-1121.
45. Jiang X., Lopez A., Holyoake T., Eaves A., Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA. 96:1999;12804-12809.
46. Zhang X., Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 92:1998;3829-3840.
47. Gordon M.Y., Dowding C.R., Riley G.P., Goldman J.M., Greaves M.F. Adhesive defects in chronic myeloid leukemia. Curr Top Microbiol Immunol. 149:1989;151-155.
48. Verfaillie C.M., McCarthy J.B., McGlave P.B. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest. 90:1992;1232-1241.
49. Salesse S., Verfaillie C.M. Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR/ABL-induced defects in integrin function in CML. Oncogene. 21:2002;8605-8611.
50. Salesse S., Verfaillie C.M. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. Oncogene. 21:2002;8547-8559.
51. Lundell B.I., McCarthy J.B., Kovach N.L., Verfaillie C.M. Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation. Leukemia. 11:1997;822-829.
52. Upadhyaya G., Guba S.C., Sih S.A., Feinberg A.P., Talpaz M., Kantarjian H.M., Deisseroth A.B., Emerson S.G. Interferon-alpha restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest. 88:1991;2131-2136.
53. Bhatia R., Wayner E.A., McGlave P.B., Verfaillie C.M. Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest. 94:1994;384-391.
54. Salgia R., Li J.L., Ewaniuk D.S., Pear W., Pisick E., Burky S.A., Ernst T., Sattler M., Chen L.B., Griffin J.D. BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest. 100:1997;46-57.
55. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
56. Pear W.S., Miller J.P., Xu L., Pui J.C., Soffer B., Quackenbush R.C., Pendergast A.M., Bronson R., Aster J.C., Scott M.L., Baltimore D. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 92:1998;3780-3792.
57. Li S., Ilaria R.L. Jr., Million R.P., Daley G.Q., Van Etten R.A. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 189:1999;1399-1412.
58. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 24:2000;57-60.
59. Sirard C., Lapidot T., Vormoor J., Cashman J.D., Doedens M., Murdoch B., Jamal N., Messner H., Addey L., Minden M., Laraya P., Keating A., Eaves A., Lansdorp P.M., Eaves C.J., Dick J.E. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood. 87:1996;1539-1548.
60. Wang J.C., Lapidot T., Cashman J.D., Doedens M., Addy L., Sutherland D.R., Nayar R., Laraya P., Minden M., Keating A., Eaves A.C., Eaves C.J., Dick J.E. High level engraftment of NOD/SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood. 91:1998;2406-2414.
61. Hoyle C.F., Negrin R.S. Engraftment of chronic myeloid leukemia in SCID mice. Hematol Oncol. 16:1998;87-100.
62. Holyoake T.L., Horrocks C., Thomas T., Eaves C.J., Eaves A.C. Cell separation improves the sensitivity of detecting rare human normal and leukemic hematopoietic cells in vivo in NOD/SCID mice. Cytotherapy. 2:2000;411-421.
63. Dazzi F., Capelli D., Hasserjian R., Cotter F., Corbo M., Poletti A., Chinswangwatanakul W., Goldman J.M., Gordon M.Y. The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology. Blood. 92:1998;1390-1396.
64. Dick J.E. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol. 8:1996;197-206.
65. Pflumio F., Izac B., Katz A., Shultz L.D., Vainchenker W., Coulombel L. Phenotype and function of human hematopoietic cells engrafting immune-deficient CB17-severe combined immunodeficiency mice and nonobese diabetic-severe combined immunodeficiency mice after transplantation of human cord blood mononuclear cells. Blood. 88:1996;3731-3740.
66. Cashman J., Bockhold K., Hogge D.E., Eaves A.C., Eaves C.J. Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood. Br J Haematol. 98:1997;1026-1036.
67. Cashman J.D., Lapidot T., Wang J.C., Doedens M., Shultz L.D., Lansdorp P., Dick J.E., Eaves C.J. Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. Blood. 89:1997;4307-4316.
68. His W. Lecithoblast und angioblast der wirbelthiere. Abhandl KS Ges Wiss Math Phys. 22:1901;171.
69. Sabin F.R. Preliminary note on the differentiation of angioblasts and the method by which they produce blood-vessels, blood-plasma and red blood cells as seen in the living chick. Anat Rec. 13:1917;199-204.
70. Shalaby F., Rossant J., Yamaguchi T.P., Gertsenstein M., Wu X.F., Breitman M.L., Schuh A.C. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:1995;62-66.
71. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., Powell-Braxton L., Hillan K.J., Moore M.W. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 380:1996;439-442.
72. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., Fahrig M., Vandenhoeck A., Harpal K., Eberhardt C., Declercq C., Pawling J., Moons L., Collen D., Risau W., Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 380:1996;435-439.
73. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., Witzenbichler B., Schatteman G., Isner J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 275:1997;964-967.
74. Gunsilius E., Duba H.C., Petzer A.L., Kahler C.M., Grunewald K., Stockhammer G., Gabl C., Dirnhofer S., Clausen J., Gastl G. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet. 355:2000;1688-1691.
75. Kvasnicka H.M., Wickenhauser C., Thiele J., Varus E., Hamm K., Beelen D.W., Schaefer U.W. Mixed chimerism of bone marrow vessels (endothelial cells, myofibroblasts) following allogeneic transplantation for chronic myelogenous leukemia. Leuk Lymphoma. 44:2003;321-328.
76. Thomas E.D., Clift R.A., Fefer A., Appelbaum F.R., Beatty P., Bensinger W.I., Buckner C.D., Cheever M.A., Deeg H.J., Doney K. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 104:1986;155-163.
77. Appelbaum F.R. Perspectives on the future of chronic myeloid leukemia treatment. Semin Hematol. 38:2001;35-42.
78. Silver R.T., Woolf S.H., Hehlmann R., Appelbaum F.R., Anderson J., Bennett C., Goldman J.M., Guilhot F., Kantarjian H.M., Lichtin A.E., Talpaz M., Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 94:1999;1517-1536.
79. Sierra J., Anasetti C. Marrow transplantation from unrelated donors. Curr Opin Hematol. 2:1995;444-451.
80. Gratwohl A., Hermans J., Goldman J.M., Arcese W., Carreras E., Devergie A., Frassoni F., Gahrton G., Kolb H.J., Niederwieser D., Ruutu T., Vernant J.P., de Witte T., Apperley J. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 352:1998;1087-1092.
81. Weisdorf D.J., Anasetti C., Antin J.H., Kernan N.A., Kollman C., Snyder D., Petersdorf E., Nelson G., McGlave P. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 99:2002;1971-1977.
82. Druker B.J. Chronic myeloid leukemia in the imatinib era. Semin Hematol. 40:2003;1-3.
83. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004.
84. Sawyers C.L., Hochhaus A., Feldman E., Goldman J.M., Miller C.B., Ottmann O.G., Schiffer C.A., Talpaz M., Guilhot F., Deininger M.W., Fischer T., O'Brien S.G., Stone R.M., Gambacorti-Passerini C.B., Russell N.H., Reiffers J.J., Shea T.C., Chapuis B., Coutre S., Tura S., Morra E., Larson R.A., Saven A., Peschel C., Gratwohl A., Mandelli F., Ben Am M., Gathmann I., Capdeville R., Paquette R.L., Druker B.J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:2002;3530-3539.
85. Talpaz M., Silver R.T., Druker B.J., Goldman J.M., Gambacorti-Passerini C., Guilhot F., Schiffer C.A., Fischer T., Deininger M.W., Lennard A.L., Hochhaus A., Ottmann O.G., Gratwohl A., Baccarani M., Stone R., Tura S., Mahon F.X., Fernandes-Reese S., Gathmann I., Capdeville R., Kantarjian H.M., Sawyers C.L. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 99:2002;1928-1937.
86. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Goldman J., O'Brien S.G., Russell N., Fischer T., Ottmann O., Cony-Makhoul P., Facon T., Stone R., Miller C., Tallman M., Brown R., Schuster M., Loughran T., Gratwohl A., Mandelli F., Saglio G., Lazzarino M., Russo D., Baccarani M., Morra E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 346:2002;645-652.
87. Goldman J.M. Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. Semin Hematol. 40:2003;10-17.
88. Gratwohl A., Baldomero H., Urbano-Ispizua A. Transplantation in chronic myeloid leukaemia. Lancet. 359:2002;712-713.
89. Goldman J., Apperley J., Clark R., Green T., Holyoake T., O'Brien S., Shepherd P. Not so NICE for, CML. Lancet. 359:2002;2036.
90. Goldman J.M., Druker B.J. Chronic myeloid leukemia: current treatment options. Blood. 98:2001;2039-2042.
91. Pigneux A., Mahon F.X., Reiffers J. Autologous peripheral blood stem cell transplantation for chronic myelocytic leukaemia, using unmanipulated grafts. Baillieres Best Pract Res Clin Haematol. 12:1999;193-198.
92. McGlave P.B., De Fabritiis P., Deisseroth A., Goldman J., Barnett M., Reiffers J., Simonsson B., Carella A., Aeppli D. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet. 343:1994;1486-1488.
93. Bhatia R., Forman S.J. Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 12:1998;151-172.
94. Deisseroth A.B., Zu Z., Claxton D., Hanania E.G., Fu S., Ellerson D., Goldberg L., Thomas M., Janicek K., Anderson W.F. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 83:1994;3068-3076.
95. Gale R.P., Horowitz M.M., Ash R.C., Champlin R.E., Goldman J.M., Rimm A.A., Ringden O., Stone J.A., Bortin M.M. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 120:1994;646-652.
96. Santos G.W. Bone marrow transplantation in leukemia. Current status. Cancer. 54:1984;2732-2740.
97. Goldman J.M., Gale R.P., Horowitz M.M., Biggs J.C., Champlin R.E., Gluckman E., Hoffmann R.G., Jacobsen S.J., Marmont A.M., McGlave P.B. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 108:1988;806-814.
98. Copelan E.A., Penza S.L., Theil K.S., Elder P.J., Bechtel T.P., Tighe M.B., Ezzone S.A., Scholl M.D., Belt P.S., Young D.C., Avalos B.R. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant. 26:2000;1037-1043.
99. Kolb H.J., Mittermuller J., Clemm C., Holler E., Ledderose G., Brehm G., Heim M., Wilmanns W. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
100. Kolb H.J. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang. 74:(Suppl 2):1998;321-329.
101. Raiola A.M., Van Lint M.T., Valbonesi M., Lamparelli T., Gualandi F., Occhini D., Bregante S., di Grazia C., Dominietto A., Soracco M., Romagnani C., Vassallo F., Casini M., Bruno B., Frassoni F., Bacigalupo A. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 31:2003;687-693.
102. Guglielmi C., Arcese W., Dazzi F., Brand R., Bunjes D., Verdonck L.F., Schattenberg A., Kolb H.J., Ljungman P., Devergie A., Bacigalupo A., Gómez M., Michallet M., Elmaagacli A., Gratwohl A., Apperley J., Niederwieser D. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 100:2002;397-405.
103. Shimoni A., Gajewski J.A., Donato M., Martin T., O'Brien S., Talpaz M., Cohen A., Korbling M., Champlin R., Giralt S. Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 7:2001;568-575.
104. Dazzi F., Szydlo R.M., Goldman J.M. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand. Exp Hematol. 27:1999;1477-1486.
105. Steegmann J.L., Casado L.F., Tomas J.F., Sanz-Rodríguez C., Granados E., de la Camara R., Alegre A., Vázquez L., Ferro M.T., Figuera A., Arranz R., Fernández-Ranada J.M. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant. 23:1999;483-488.
106. Giralt S., O'Brien S., Talpaz M., Van Besien K., Chan K.W., Rondon G., Andersson B., Mehra R., Khouri I., Estey E. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1:1995;115-122.
107. Higano C.S., Chielens D., Raskind W., Bryant E., Flowers M.E., Radich J., Clift R., Appelbaum F. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood. 90:1997;2549-2554.
108. Das M., Saikia T.K., Advani S.H., Parikh P.M., Tawde S. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant. 32:2003;125-129.
109. Or R., Shapira M.Y., Resnick I., Amar A., Ackerstein A., Samuel S., Aker M., Naparstek E., Nagler A., Slavin S. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 101:2003;441-445.
110. Marks D.I., Lush R., Cavenagh J., Milligan D.W., Schey S., Parker A., Clark F.J., Hunt L., Yin J., Fuller S., Vandenberghe E., Marsh J., Littlewood T., Smith G.M., Culligan D., Hunter A., Chopra R., Davies A., Towlson K., Williams C.D. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 100:2002;3108-3114.
111. Kreuzer K.A., Schmidt C.A., Schetelig J., Held T.K., Thiede C., Ehninger G., Siegert W. Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia. Eur J Haematol. 69:2002;7-10.
112. Okamoto S., Watanabe R., Takahashi S., Mori T., Izeki T., Nagayama H., Ishida A., Takayama N., Yokoyama K., Tojo A., Asano S., Ikeda Y. Long-term follow-up of allogeneic bone marrow transplantation after reduced-intensity conditioning in patients with chronic myelogenous leukemia in the chronic phase. Int J Hematol. 75:2002;493-498.
113. Pawson R., Potter M.N., Theocharous P., Lawler M., Garg M., Yin J.A., Rezvani K., Craddock C., Rassam S., Prentice H.G. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol. 115:2001;622-629.
114. Raiola A.M., Van Lint M.T., Lamparelli T., Gualandi F., Mordini N., Berisso G., Bregante S., Frassoni F., Sessarego M., Fugazza G., Di Stefano F., Pitto A., Bacigalupo A. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol. 109:2000;716-721.
115. Niederwieser D., Maris M., Shizuru J.A., Petersdorf E., Hegenbart U., Sandmaier B.M., Maloney D.G., Storer B., Lange T., Chauncey T., Deininger M., Ponisch W., Anasetti C., Woolfrey A., Little M.T., Blume K.G., McSweeney P.A., Storb R.F. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 101:2003;1620-1629.
116. Feinstein L., Storb R. Reducing transplant toxicity. Curr Opin Hematol. 8:2001;342-348.
117. Carella A.M., Champlin R., Slavin S., McSweeney P., Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant. 25:2000;345-350.
118. Weinberger A., Benjamin D., Douer D., Barabash G., Djaldetti M., Pinkhas J. A 13-year remission in chronic myelocytic leukemia after a single course of busulfan. Acta Haematol. 59:1978;354-359.
119. Carella A.M. Mini-ICE protocol is better than high-dose hydroxyurea to mobilize Ph-negative cells in earlier phases of chronic myelogenous leukemia. Leuk Lymphoma. 31:1998;437-438.
120. Carella A.M., Cunningham I., Lerma E., Dejana A., Benvenuto F., Podesta M., Celesti L., Chimirri F., Abote M., Vassallo F., Figari O., Parodi C., Sessarego M., Valbonesi M., Carlier P., Prencipe E., Gatti A.M., van den Berg D., Hoffman R., Frassoni F. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol. 15:1997;1575-1582.
121. Carella A.M., Frassoni F., Podesta M., Pungolino E., Pollicardo N., Ferrero R., Soracco M. Idarubicin, intermediate-dose cytarabine, etoposide, and granulocyte-colony-stimulating factor are able to recruit CD34+/HLA-DR- cells during early hematopoietic recovery in accelerated and chronic phases of chronic myeloid leukemia. J Hematother. 3:1994;199-202.
122. Carella A.M., Pollicardo N., Pungolino E., Raffo M.R., Podesta M., Ferrero R., Pierluigi D., Nati S., Naibo K., Congiu A. Mobilization of cytogenetically 'normal' blood progenitors cells by intensive conventional chemotherapy for chronic myeloid and acute lymphoblastic leukemia. Leuk Lymphoma. 9:1993;477-483.
123. Bhatia R., Verfaillie C.M., Miller J.S., McGlave P.B. Autologous transplantation therapy for chronic myelogenous leukemia. Blood. 89:1997;2623-2634.
124. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566.
125. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
126. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood. 99:2002;3792-3800.
127. Bhatia R., Holtz M., Niu N., Gray R., Snyder D.S., Sawyers C.L., Arber D.A., Slovak M.L. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 101:2003;4701-4707.
128. Petzer A.L., Gunsilius E., Duba H.C., Elahi F., Hoflehner E., Haun M., Wolf D., Thaler J., Geissler K., Grunewald K., Woell E., Gastl G., Keil F. Selective in-vivo effect of imatinib mesylate on BCR-ABL+ progenitors (CFC, LTC-IC) in the bone marrow of CML patients in chronic and accelerated phase on treatment with imatinib mesylate after failure or intolerance to interferon alpha. (abstract 1432) Blood. 100:2002;370a.
129. Graham S.M., Jorgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 99:2002;319-325.
130. Moore S., Haylock D.N., Levesque J.P., McDiarmid L.A., Samels L.M., To L.B., Simmons P.J., Hughes T.P. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells. Blood. 92:1998;2461-2470.
131. Lewis I.D., McDiarmid L.A., Samels L.M., To L.B., Hughes T.P. Establishment of a reproducible model of chronic-phase chronic myeloid leukemia in NOD/SCID mice using blood-derived mononuclear or CD34+ cells. Blood. 91:1998;630-640.
132. Agarwal R., Doren S., Hicks B., Dunbar C.E. Long-term culture of chronic myelogenous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood. 85:1995;1306-1312.
133. Hallek M., Danhauser-Riedl S., Herbst R., Warmuth M., Winkler A., Kolb H.J., Druker B., Griffin J.D., Emmerich B., Ullrich A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells. Br J Haematol. 94:1996;5-16.